From natural polyphenols to synthetic antitumor agents

Bioactive Compounds from Natural Sources: Natural Products as Lead Compounds in Drug Discovery, Second Edition

Volumn , Issue , 2011, Pages 299-338

  Spatafora, Carmela ^a   Tringali, Corrado ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85034312610     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (168)

1. Achanta, G., A. Modzelewska, L. Feng, S. R. Khan, and P. Huang. 2006. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. Mol. Pharmacol. 70: 426-433.
2. Adams, B. K., E. M. Ferstl, M. C. Davis, M. Herold, S. Kurtkaya, R. F. Camalier, M. G. Hollingshead et al. 2004. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg. Med. Chem. 12: 3871-3873.
3. Aggarwal, B. B., A. Bhardwaj, R. S. Aggarwal, N. P. Seeram, S. Shishodia, and Y. Takada. 2004. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res. 24: 2783-2840.
4. Aggarwal, B. B. and S. Shishodia. 2006a. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71: 1397-1421.
5. Aggarwal, B. B. and S. Shishodia. 2006b. Oxidative Stress and Disease, Vol. 20. Resveratrol in health and disease. London, U.K.: Taylor & Francis.
6. Ahn, Y. M., L. Vogeti, C.-J. Liu Santhapuram, K. R. Hari, J. M. White, V. Vasandani, L. A. Mitscher et al. 2007. Design, synthesis, and antiproliferative and CDK2-cyclin A inhibitory activity of novel flavopiridol analogues. Bioorg. Med. Chem. 15: 702-713.
7. Albini, A., R. Dell’Eva, R. Vene, N. Ferrari, D. R. Buhler, D. M. Noonan, and G. Fassina. 2006. Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-κB and Akt as targets. FASEB J. 20: 527-529.
8. Aleo, D., V. Cardile, R. Chillemi, G. Granata, and S. Sciuto. 2008. Chemoenzymatic synthe¬sis and some biological properties of O-phosphoryl derivatives of (E)-resveratrol. Nat. Prod. Comm. 3: 1693-1700.
9. Almond, J. B. and G. M. Cohen. 2002. The proteasome: A novel target for cancer chemo¬therapy. Leukemia 16: 433-443.
10. Apers, S., D. Paper, J. Buergermeister, S. Baronikova, S. Van Dyck, G. Lemiere, A. Vlietinck, and L. Pieters. 2002. Antiangiogenic activity of synthetic dihydrobenzofuran lignans. J. Nat. Prod. 65: 718-720.
11. Apers, S., A. Vlietinck, and L. Pieters. 2003. Lignans and neolignans as lead compounds. Phytochem. Rev. 2: 201-217.
12. Ayers, D. C. and J. D. Loike. 1990. Lignans. Chemical, Biological and Clinical Properties. Cambridge, U.K.: Cambridge University Press.
13. Bandgar, B. P., S. S. Gawande, R. G. Bodade, J. V. Totre, and C. N. Khobragade. 2010. Synthesis and biological evaluation of simple methoxylated chalcones as anticancer, anti-inflammatory and antioxidant agents. Bioorg. Med. Chem. 18: 1364-1370.
14. Banerjee, S., Z. Wang, M. Mohammad, F. H. Sarkar, and R. M. Mohammad. 2008. Efficacy of selected natural products as therapeutic agents against cancer. J. Nat. Prod. 71: 492-496.
15. Basile, V., E. Ferrari, S. Lazzari, S. Belluti, F. Pignedoli, and C. Imbriano. 2009. Curcumin derivatives: Molecular basis of their anti-cancer activity. Biochem. Pharmacol. 78: 1305-1315.
16. Basini, G., L. Baioni, S. Bussolanti, F. Grasselli, C. Daquino, C. Spatafora, and C. Tringali. 2010a. Antiangiogenic properties of an unusual benzo[k, l]xanthene lignan derived from CAPE (Caffeic Acid Phenethyl Ester). Invest. New Drug. In press, DOI 10.1007/s10637-010-9550-z.
17. Basini, G., C. Tringali, L. Baioni, S. Bussolati, C. Spatafora, and F. Grasselli. 2010b. Biological effects on granulosa cells of hydroxylated and methylated resveratrol analogues. Mol. Nutr. Food Res. 54: S236-S243.
18. Baur, J. A. and D. A. Sinclair. 2006. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov. 5: 493-506.
19. Belleri, M., D. Ribatti, S. Nicoli, F. Cotelli, L. Forti, V. Vannini, L. A. Stivala, and M. Presta. 2005. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4′-trimethoxystilbene. Mol. Pharmacol. 67: 1451-1459.
20. Beltran-Ramirez, O., L. Aleman-Lazarini, M. Salcido-Neyoyet, S. Hernandez-Garcia, S. Fattel-Fazenda, E. Arce-Popoca, J. Arellanes-Robledo et al. 2008. Evidence that the anticarcinogenic effect of caffeic acid phenethyl ester in the resistant hepatocyte model involves modifications of cytochrome P450. Toxicol. Sci. 104: 100-106.
21. Bemis, D. L., A. E. Katz, and R. Buttyan. 2006. Clinical trials of natural products as chemo¬preventive agents for prostate cancer. Expert Opin. Investig. Drugs 15: 1191-1200.
22. Bernhaus, A., M. Fritzer-Szekeres, M. Grusch, P. Saiko, G. Krupitza, S. Venkateswarlu, G. Trimurtulu, W. Jaeger, and T. Szekeres. 2009a. Digalloylresveratrol, a new phenolic acid derivative induces apoptosis and cell cycle arrest in human HT-29 colon cancer cells. Cancer Lett. 274: 299-304.
23. Bernhaus, A., M. Ozsvar-Kozma, P. Saiko, M. Jaschke, A. Lackner, M. Grusch, Z. Horvath et al. 2009b. Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells. Invest. New Drugs 27: 393-401.
24. Bhakuni, D. S. and R. Chaturvedi. 1984. Chemical constituents of Crotalaria madurensis. J. Nat. Prod. 47: 585-591.
25. Bohlin, L. and B. Rosen. 1996. Podophyllotoxin derivatives: Drug discovery and develop¬ment. Drug Discov. Today 1: 343-351.
26. Bonfili, L., V. Cecarini, M. Amici, M. Cuccioloni, M. Angeletti, J. N. Keller, and A. M. Eleuteri. 2008. Natural polyphenols as proteasome modulators and their role as anti-cancer com¬pounds. FEBS J. 275: 5512-5526.
27. Bose, J. S., V. Gangan, R. Prakash, S. K. Jain, and S. K. Manna. 2009. A dihydrobenzofuran lignan induces cell death by modulating mitochondrial pathway and G2/M cell cycle arrest. J. Med. Chem. 52: 3184-3190.
28. Boudet, A.-M. 2007. Evolution and current status of research in phenolic compounds. Phytochemistry 68: 2722-2735.
29. Boumendjel, A., J. Boccard, P.-A. Carrupt, E. Nicolle, M. Blanc, A. Geze, L. Choisnard, D. Wouessidjewe, E.-L. Matera, and C. Dumontet. 2008. Antimitotic and antiprolifera¬tive activities of chalcones: Forward structure-activity relationship. J. Med. Chem. 51: 2307-2310.
30. Boumendjel, A., A. McLeer-Florin, P. Champelovier, D. Allegro, D. Muhammad, F. Souard, M. Derouazi, V. Peyrot, B. Toussaint, and J. Boutonnat. 2009. A novel chalcone deriva¬tive which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models. BMC Cancer 9: 242.
31. Burjonroppa, S. and K. Fujise. 2006. Resveratrol as cardioprotective agent: Evidence from bench and bedside. In Resveratrol in Health and Disease, eds. B. B. Aggarwal and S. Shishodia, pp. 539-555. London, U.K.: Taylor & Francis.
32. Cao, T. M., D. Durrant, A. Tripathi, J. Liu, S. Tsai, G. E. Kellogg, D. Simoni, and R. M. Lee. 2008. Stilbene derivatives that are colchicine site microtubule inhibitors have antileuke¬mic activity and minimal systemic toxicity. Am. J. Hematol. 83: 390-397.
33. Cardenas, M., M. Marder, V. C. Blank, L. P. Roguin, and P. Leonor. 2006. Antitumor activity of some natural flavonoids and synthetic derivatives on various human and murine can¬cer cell lines. Bioorg. Med. Chem. 14: 2966-2971.
34. Cardile, V., R. Chillemi, L. Lombardo, S. Sciuto, C. Spatafora, and C. Tringali. 2007. Antiproliferative activity of methylated analogues of E- and Z-resveratrol. Z. Naturforsch. 62c: 189-195.
35. Cardile, V., L. Lombardo, C. Spatafora, and C. Tringali. 2005. Chemo-enzymatic synthesis and antiproliferative activity of resveratrol analogues. Bioorg. Chem. 33: 22-33.
36. Chang, J.-Y., M.-F. Yang, C.-Y. Chang, C.-M. Chen, C.-C. Kuo, and J.-P. Liou. 2006. 2-Amino and 2′-aminocombretastatin derivatives as potent antimitotic agents. J. Med. Chem. 49: 6412-6415.
37. Chaudhary, A., S. N. Pandeya, P. Kumar, P. P. Sharma, S. Gupta, N. Soni, K. K. Verma, and G. Bhardwaj. 2007. Combretastatin A-4 analogs as anticancer agents. Mini Rev. Med. Chem. 7: 1186-1205.
38. Chen, L. and H.-Y. Zhang. 2007. Cancer preventive mechanisms of the green tea polyphenol (-)-epigallocatechin-3-gallate. Molecules 12: 946-957.
39. Cheng, L., H. Tan, X. Wu, R. Hu, C. Aw, M. Zhao, H.-M. Shen, and Y. Lu. 2008. Novel syn¬thetic luteolin analogue-caused sensitization of tumor necrosis factor-α-induced apopto¬sis in human tumor cells. Org. Biom. Chem. 6: 4102-4104.
40. Chillemi, R., S. Sciuto, C. Spatafora, and C. Tringali. 2007. Anti-tumor properties of stilbene-based resveratrol analogues: Recent results. Nat. Prod. Comm. 2: 499-513.
41. Cushman, M., D. Nagarathnam, D. Gopal, A. K. Chakraborti, C. M. Lin, and E. Hamel. 1991. Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential antican¬cer agents that inhibit tubulin polymerization. J. Med. Chem. 34: 2579-2588.
42. Daquino, C., A. Rescifina, C. Spatafora, and C. Tringali. 2009. Biomimetic synthesis of natu¬ral and “unnatural” lignans by oxidative coupling of caffeic esters. Eur. J. Org. Chem. 6289-6300.
43. De Lemos, M. L. 2001. Effects of soy phytoestrogens genistein and daidzein on breast cancer growth. Ann. Pharmacother. 35: 1118-1121.
44. Delmas, D., A. Lançon, D. Colin, B. Jannin, and N. Latruffe. 2006. Resveratrol as a chemopre¬ventive agent: A promising molecule for fighting cancer. Curr. Drug Targets 7: 423-442.
45. Dewick, P. M. 2009. Medicinal Natural Products: A Biosynthetic Approach, 3rd edn., pp. 1-539. Chichester, U.K.: J. Wiley.
46. Di Micco, S., C. Daquino, C. Spatafora, F. Mazué, D. Delmas, N. Latruffe, C. Tringali, R. Riccio, and G. Bifulco. 2011. Structural basis for the potential antitumor activity of DNA-interacting Benzo[kl]xanthene lignans. Org. Biomol. Chem. 9: 701-710.
47. Donnelly, A. C., J. R. Mays, J. A. Burlison, J. T. Nelson, G. Vielhauer, J. Holzbeierlein, and B. S. J. Blagg. 2008. The design, synthesis, and evaluation of coumarin ring deriva¬tives of the novobiocin scaffold that exhibit antiproliferative activity. J. Org. Chem. 73: 8901-8920.
48. Ducki, S., G. MacKenzie, B. Greedy, S. Armitage, J. Fournier Dit Chabert, E. Bennett, J. Nettles, J. P. Snyder, and N. J. Lawrence. 2009a. Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones. Bioorg. Med. Chem. 17: 7711-7722.
49. Ducki, S., G. Mackenzie, N. J. Lawrence, and J. P. Snyder. 2005. Quantitative structure-activity relationship (5D-QSAR) study of combretastatin-like analogues as inhibitors of tubulin assembly. J. Med. Chem. 48: 457-465.
50. Ducki, S., D. Rennison, M. Woo, A. Kendall, J. Fournier Dit Chabert, A. T. McGown, and N. J. Lawrence. 2009b. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity. Bioorg. Med. Chem. 17: 7698-7710.
51. East, A. J., W. D. Ollis, and R. E. Wheeler. 1969. Natural occurrence of 3-aryl-4-hydroxycou¬marins. I. Phytochemical examination of Derris robusta. J. Chem. Soc. C 3: 365-374.
52. El-Refaei, M. F. and M. M. El-Naa. 2010. Inhibitory effect of caffeic acid phenethyl ester on mice bearing tumor involving angiostatic and apoptotic activities. Chem. Bio. Interact. 186: 152-156.
53. Etzenhouser, B., C. Hansch, S. Kapur, and C. D. Selassie. 2001. Mechanism of toxicity of esters of caffeic and dihydrocaffeic acids. Bioorg. Med. Chem. 9: 199-209.
54. Ferreira, M.-J. U., N. Duarte, N. Gyémánt, R. Radics, G. Cherepnev, A. Varga, and J. Molnar. 2006. Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells. Anticancer Res. 26: 3541-3546.
55. Fiuza, S. M., C. Gomes, L. J. Teixeira, M. T. Girao da Cruz, M. N. D. S. Cordeiro, N. Milhazes, F. Borges, and M. P. M. Marques. 2004. Phenolic acid derivatives with potential antican¬cer properties: A structure-activity relationship study. Part 1: Methyl, propyl and octyl esters of caffeic and gallic acids. Bioorg. Med. Chem. 12: 3581-3589.
56. Flørenesd, V. A. and T. V. Hansen. 2008. 1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modelling and evaluation as cytotoxic agents and inhibitors of tubulin. Bioorg. Med. Chem. 16: 4829-4838.
57. Fujiki, H., M. Suganuma, K. Imai, and K. Nakachi. 2002. Green tea: Cancer preventive bever¬age and/or drug. Cancer Lett. 188: 9-13.
58. Go, M. L., X. Wu, and X. L. Liu. 2005. Chalcones: An update on cytotoxic and chemopreven¬tive properties. Curr. Med. Chem. 12: 483-499.
59. Gordaliza, M., M. A. Castro, J. M. Miguel del Corral, and A. San Feliciano. 2000. Antitumor properties of podophyllotoxin and related compounds. Curr. Pharm. Des. 6: 1811-1839.
60. Gupta, D., B. Bleakley, and R. K. Gupta. 2008. Dragon’s blood: Botany, chemistry and thera¬peutic uses. J. Ethnopharmacol. 115: 361-380.
61. Hackett, J. C., Y.-W. Kim, B. Su, and R. W. Brueggemeier. 2005. Synthesis and characteriza¬tion of azole isoflavone inhibitors of aromatase. Bioorg. Med. Chem. 13: 4063-4070.
62. Hadden, M. K., L. Galam, R. L. Matts, and B. S. J. Blagg. 2007. Derrubone, an inhibitor of the Hsp90 protein folding machinery. J. Nat. Prod. 70: 2014-2018.
63. Hadfield, J. A., K. Gaukroger, N. Hirst, A. P. Weston, N. J. Lawrence, and A. T. McGown. 2005. Synthesis and evaluation of double bond substituted combretastatins. Eur. J. Med.Chem. 40: 529-541.
64. Haslam, E. 1998. Practical Polyphenolics: From Structure to Molecular Recognition and Physiological Action. Cambridge, U.K.: Cambridge University Press.
65. Hayes, C. J., B. P. Whittaker, S. A. Watson, and A. M. Grabowska. 2006. Synthesis and pre¬liminary anticancer activity studies of C4 and C8-modified derivatives of catechin gal¬late (CG) and epicatechin gallate (ECG). J. Org. Chem. 71: 9701-9712.
66. Hill, S. A., G. M. Tozer, G. R. Pettit, and D. J. Chaplin. 2002. Preclinical evaluation of the antitumor activity of the novel vascular-targeting agent Oxi 4503. Anticancer Res. 22: 1453-1458. http://www.groupepolyphenols.com
67. Huang, X.-F., B.-F. Ruan, X.-T. Wang, C. Xu, H.-M. Ge, H.-L. Zhu, and R.-X. Tan. 2007. Synthesis and cytotoxic evaluation of a series of resveratrol derivatives modified in C2 position. Eur. J. Med. Chem. 42: 263-267.
68. Huo, C., S. B. Wan, W. H. Lam, L. Li, Z. Wang, K. R. Landis-Piwowar, D. Chen, Q. P. Dou, and T. H. Chan. 2008. The challenge of developing green tea polyphenols as therapeutic agents. Inflammopharmacology 16: 248-252.
69. Imai, K., K. Suga, and K. Nakachi. 1997. Cancer-preventive effects of drinking green tea among a Japanese population. Prev. Med. 26: 769-775.
70. Imbert, T. F. 1998. Discovery of podophyllotoxins. Biochimie 80: 207-222.
71. Itokawa, H., Q. Shi, T. Akiyama, S. L. Morris-Natschke, and K.-H. Lee. 2008. Recent advances in the investigation of curcuminoids. Chin. Med. 3: 11.
72. Jang, M., L. Cai, G. O. Udeani et al. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
73. Jayaprakasam, B., M. Vanisree, Y. Zhang, D. L. Dewitt, and M. G. Nair. 2006. Impact of alkyl esters of caffeic and ferulic acids on tumor cell proliferation, cyclooxygenase enzyme, and lipid peroxidation. J. Agric. Food Chem. 54: 5375-5381.
74. Jazirehi, A. R. and B. Bonavida. 2006. Resveratrol as a sensitizer to apoptosis-inducing stimuli. In Resveratrol in Health and Disease, eds. B. B. Aggarwal and S. Shishodia, pp. 399-421. London, U.K.: Taylor & Francis.
75. Jeong, S. H., W. S. Jo, S. Song, H. Suh, S.-Y. Seol, S.-H. Leem, T. K. Kwon, and Y. H. Yoo. 2009. A novel resveratrol derivative, HS1793, overcomes the resistance conferred by Bcl-2 in human leukemic U937 cells. Biochem. Pharmacol. 77: 1337-1347.
76. Kanthou, C. and G. M. Tozer. 2007. Tumor targeting by microtubule-depolymerising vascular disrupting agents. Expert Opin. Ther. Targets 11: 1443-1457.
77. Katalinic, V., S. S. Mozina, D. Skroza, I. Generalic, H. Abramovic, M. Milos, I. Ljubenkov et al. 2009. Polyphenolic profile, antioxidant properties and antimicrobial activity of grape skin extracts of 14 Vitis vinifera varieties grown in Dalmatia (Croatia). Food Chem. 119: 715-723.
78. Katsori, A. M. and D. Hadjipavlou-Litina. 2009. Chalcones in cancer: Understanding their role in terms of QSAR. Curr. Med. Chem. 16: 1062-1081.
79. Kim, Y. W., J. C. Hackett, and R. W. Brueggemeier. 2004. Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones. J. Med. Chem. 47: 4032-4040.
80. Kingston, D. G. I. 2009. Tubulin-interactive natural products as anticancer agents. J. Nat. Prod. 72: 507-515.
81. Kong, Y., J. Grembecka, M. C. Edler, E. Hamel, S. L. Mooberry, M. Sabat, J. Rieger, and M. L. Brown. 2005. Structure-based discovery of a boronic acid bioisostere of combre¬tastatin A-4. Chem. Biol. 12: 1007-1014.
82. Kong, Y., K. Wang, M. C. Edler, E. Hamel, S. L. Mooberry, M. A. Paigeand, and M. L. Brown. 2010. A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent. Bioorg. Med. Chem. 18: 971-977.
83. Kumar, S. K., E. Hager, C. Pettit, H. Gurulingappa, N. E. Davidson, and S. R. Khan. 2003. Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. J. Med. Chem. 46: 2813-2815.
84. Labbozzetta, M., M. Notarbartolo, P. Poma, A. Maurici, L. Inguglia, P. Marchetti, M. Rizzi, R. Baruchello, D. Simoni, and N. D’Alessandro. 2009. Curcumin as a possible lead compound against hormone-independent, multidrug-resistant breast cancer. Steroid enzymes and cancer. Ann. N. Y. Acad. Sci. 1155: 278-283.
85. Lambert, J. D., S. Sang, J. Hong, S.-J. Kwon, M.-J. Lee, C.-T. Ho, and C. S. Yang. 2006. Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigal¬locatechin-3-gallate. Drug Metab. Dispos. 34: 2111-2116.
86. Lamy, S., D. Gingras, and R. Béliveau. 2002. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res. 62: 381-385.
87. Lançon, A., N. Hanet, B. Jannen, D. Delmas, J.-M. Heyuel, G. Lizard, M.-C. Chagnot, Y. Artur, and N. Latruffe. 2007. Resveratrol in human hepatoma HepG2 cells: Metabolism and inducibility of detoxifying enzymes. Drug Metab. Dispos. 35: 699-703.
88. Landis-Piwowar, K. R., C. Huo, D. Chen, V. Milacic, G. Shi, T. H. Chan, and Q. P. Dou. 2007. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a poten¬tial anticancer agent. Cancer Res. 67: 4303-4310.
89. Le Marchand, L., S. P. Murphy, J. H. Hankin, L. R. Wilkens, and L. N. Kolonel. 2000. Intake of flavonoids and lung cancer. J. Natl. Cancer Inst. 92: 154-160.
90. Lee, Y. J., P. H. Liao, W. K. Chen, and C. Y. Yang. 2000. Preferential cytotoxicity of caffeic acid phenethyl ester analogues on oral cancer cells. Cancer Lett. 153: 51-56.
91. Lee, K.-H. and Z. Xiao. 2003. Lignans in treatment of cancer and other diseases. Phytochem. Rev. 2: 341-362.
92. Lemiere, G., M. Gao, A. De Groot, R. Dommisse, J. Lepoivre, L. Pieters, and V. Buss. 1995. 3′,4-Di-O-methylcedrusin: Synthesis, resolution and absolute configuration. J. Chem. Society, Perkin Trans. 18: 11775-11779.
93. Li, H.-Q., H.-M. Ge, Y.-X. Chen, C. Xu, L. Shi, H. Ding, H.-L. Zhu, and R.-X. Tan. 2006. Synthesis and cytotoxic evaluation of a series of genistein derivatives. Chem. Biodivers. 3: 463-472.
94. Lin, H. S. and P. C. Ho. 2009. A rapid HPLC method for the quantification of 3,5,4′-trime¬thoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacokinetic study. J. Pharm. Biomed. Anal. 49: 387-392.
95. Lin, T. S., A. S. Ruppert, A. J. Johnson, B. Fischer, N. A. Heerema, L. A. Andritsos, K. A. Blum et al. 2009. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demon¬strating high response rates in genetically high-risk disease. J. Clin. Oncol. 27: 6012-6018.
96. Lin, L., Q. Shi, A. K. Nyarko, F. Kenneth, C.-C. Wu, C.-Y. Su, C. C.-Y. Shih, and K.-H. Lee. 2006a. Antitumor agents. 250. Design and synthesis of new curcumin analogues as poten¬tial anti-prostate cancer agents. J. Med. Chem. 49: 3963-3972.
97. Lin, L., Q. Shi, C.-Y. Su, C. C.-Y. Shih, and K.-H. Lee. 2006b. Antitumor agents 247. New 4-ethoxycarbonylethyl curcumin analogs as potential antiandrogenic agents. Bioorg. Med. Chem. 14: 2527-2534.
98. Lin, H.-S., C. Tringali, C. Spatafora, Q.-Y. Choo, and P. C. Ho. 2010. LC determination of trans-3,5,3′,4′,5′-pentamethoxystilbene in rat plasma. Chromatographia 72: 827-832.
99. Liu, Y.-Q., L. Yang, and X. Tian. 2007. Podophyllotoxin: Current perspectives. Curr. Bioact. Compd. 3: 37-66.
100. Losiewicz, M. D., B. A. Carlson, G. Kaur, E. A. Sausville, and P. J. Worland. 1994. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. 201: 589-595.
101. Lv, P.-C., K.-R. Wang, Q.-S. Li, J. Chen, J. Sun, and H.-L. Zhu. 2010. Design, synthesis and biological evaluation of chrysin long-chain derivatives as potential anticancer agents. Bioorg. Med. Chem. 18: 1117-1123.
102. MacRae, W. D. and G. H. N. Towers. 1985. Non-alkaloidal constituents of Virola elongate bark. Phytochemistry 24: 561-566.
103. Magedov, I. V., M. Manpadi, E. Rozhkova, N. M. Przheval’skii, S. Rogelj, S. T. Shors, W. F. A. Steelant, S. Van Slambrouck, and A. Kornienko. 2007. Structural simplification of bio¬active natural products with multicomponent synthesis: Dihydropyridopyrazole ana¬logues of podophyllotoxin. Bioorg. Med. Chem. Lett. 17: 1381-1385.
104. Manthey, J. A. and N. Guthrie. 2002. Antiproliferative activities of Citrus flavonoids against six human cancer cell lines. J. Agric. Food Chem. 50: 5837-5843.
105. Matsubara, K., A. Saito, A. Tanaka, N. Nakajima, R. Akagi, M. Mori, and Y. Mizushina. 2007. Epicatechin conjugated with fatty acid is a potent inhibitor of DNA polymerase and angiogenesis. Life Sci. 80: 1578-1585.
106. Matsumura, K., K. Kaihatsu, S. Mori, H. H. Cho, N. Kato, and S. H. Hyon. 2008. Enhanced antitumor activities of (-)-epigallocatechin-3-O-gallate fatty acid monoester derivatives in vitro and in vivo. Biochem. Biophys. Res. Comm. 377: 1118-1122.
107. Mazué, F., D. Colin, J. Gobbo, M. Wegner, A. Rescifina, C. Spatafora, D. Fasseur et al. 2010. Structural determinants of resveratrol for cell proliferation inhibition potency: Experimental and docking studies of new analogs. Eur. J. Med. Chem. 45: 2972-2980.
108. Minutolo, F., G. Sala, A. Bagnacani, S. Bertini, I. Carboni, G. Placanica, G. Prota et al. 2005. Synthesis of a resveratrol analogue with high ceramide-mediated proapoptotic activity on human breast cancer cells. J. Med. Chem. 48: 6783-6786.
109. Modzelewska, A., C. Pettit, G. Achanta, N. E. Davidson, P. Huang, and S. R. Khan. 2006. Anticancer activities of novel chalcone and bis-chalcone derivatives. Bioorg. Med. Chem. 14: 3491-3495.
110. Mohanakumara, P., N. Sreejayan, V. Priti, B. T. Ramesha, G. Ravikanth, K. N. Ganeshaiah, R. Vasudeva et al. 2010. Dysoxylum binectariferum Hook.f (Meliaceae), a rich source of rohitukine. Fitoterapia 81: 145-148.
111. Moran, B. W., F. P. Anderson, A. Devery, S. Cloonan, W. E. Butler, S. Varughese, S. M. Draper, and P. T. M. Kenny. 2009. Synthesis, structural characterisation and biological evalua¬tion of fluorinated analogues of resveratrol. Bioorg. Med. Chem. 17: 4510-4522.
112. Mosley, C. A., D. C. Liotta, and J. P. Snyder. 2007. Highly active anticancer curcumin ana¬logues. Adv. Exp. Med. Biol. 595: 77-103.
113. Musa, M. A., J. S. Cooperwood, and M. O. F. Khan. 2008. A review of coumarin derivatives in pharmacotherapy of breast cancer. Curr. Med. Chem. 15: 2664-2679.
114. Nagle, D. G., D. Ferreira, and Y.-D. Zhou. 2006. Epigallocatechin-3-gallate (EGCG): Chemical and biomedical perspectives. Phytochemistry 67: 1849-1855.
115. Nichenametla, S. N., T. G. Taruscio, D. L. Barney, and J. H. Exon. 2006. A review of the effects and mechanisms of polyphenolics in cancer. Crit. Rev. Food Sci. Nutr. 46: 161-183.
116. Nicolosi, G., C. Spatafora, and C. Tringali. 2002. Chemo-enzymatic preparation of resveratrol derivatives. J. Mol. Catal. B Enzym. 16: 223-229.
117. Noble, M. E. M., J. A. Endicott, and L. N. Johnson. 2004. Protein kinase inhibitors: Insights into drug design from structure. Science 303: 1800-1805.
118. Nonomura, S., H. Kanagawa, and A. Makimoto. 1963. Chemical constituents of polygona¬ceous plants. I. Studies on the components of Ko-jo-kon (Polygonum cuspidatum Sieb. et Zucc.). Yakugaku Zasshi 83: 988-990.
119. Odlo, K., J. Fournier-Dit-Chabert, S. Ducki, O. A. B. S. M. Gani, I. Sylte, and T. V. Hansen. 2010. 1,2,3-Triazole analogs of combretastatin A-4 as potential microtubule-binding agents. Bioorg. Med. Chem. 18: 6874-6885.
120. Ohori, H., H. Yamakoshi, M. Tomizawa, M. Shibuya, Y. Kakudo, A. Takahashi, and S. Takahashi. 2006. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol. Cancer Ther. 5: 2563-2571.
121. Pan, J.-Y., S.-L. Chen, M.-H. Yang, J. Wu, J. Sinkkonen, and K. Zous. 2009. An update on lignans: Natural products and synthesis. Nat. Prod. Rep. 26: 1251-1292.
122. Pan, M.-H., C.-L. Lin, J.-H. Tsai, C.-T. Ho, and W.-J. Chen. 2010. 3,5,3′,4′,5′-Pentamethoxystilbene (MR-5), a synthetically methoxylated analogue of resveratrol, inhibits growth and induces G1 cell cycle arrest of human breast carcinoma MCF-7 cells. J. Agric. Food Chem. 58: 226-334.
123. Pettit, G. R., N. Melody, A. Thornhill, J. C. Knight, T. L. Groy, and C. L. Herald. 2009a. Antineoplastic agents. 579. Synthesis and cancer cell growth evaluation of E-stilstatin 3: A resveratrol structural modification. J. Nat. Prod. 72: 1637-1642.
124. Pettit, R. K., G. R. Pettit, E. Hamel, F. Hogan, B. R. Moser, S. Wolf, S. Pon, J.-C. Chapuis, and J. M. Schmidt. 2009b. E-Combretastatin and E-resveratrol structural modifications: Antimicrobial and cancer cell growth inhibitory β-E-nitrostyrenes. Bioorg. Med. Chem. 17: 6606-6612.
125. Pettit, G. R., S. B. Singh, E. Hamel, C. M. Lin, D. S. Alberts, and K. D. Garcia. 1989. Experientia 45: 209-211.
126. Pettit, G. R., A. J. Thornhill, B. R. Moser, and F. Hogan. 2008. Antineoplastic agents. 552. Oxidation of combretastatin A-1: Trapping the o-quinone intermediate considered the metabolic product of the corresponding phosphate prodrug. J. Nat. Prod. 71: 1561-1563.
127. Pieters, L., S. Van Dyck, M. Gao, R. Bai, E. Hamel, A. Vlietinck, and G. Lemiere. 1999. Synthesis and biological evaluation of dihydrobenzofuran lignans and related com¬pounds as potential antitumor agents that inhibit tubulin polymerization. J. Med. Chem. 42: 5475-5481.
128. Pinney, K. G., C. Jelinek, K. Edvardsen, D. J. Chaplin, and G. R. Pettit. 2005. The discovery and development of the combrestatins. In Anticancer Agents from Natural Products, eds. G. M. Cragg, D. G. I. Kingston, and D. J. Newman, pp. 23-46. Boca Raton, FL: CRC Press.
129. Pirali, T., S. Busacca, L. Beltrami, D. Imovilli, F. Pagliai, G. Miglio, A. Massarotti et al. 2006. Synthesis and cytotoxic evaluation of combretafurans, potential scaffolds for dual-action antitumoral agents. J. Med. Chem. 49: 5372-5376.
130. Quideau, S. 2006. Why bother with polyphenols? Polyphénols Actualités 24: 10-14.
131. Quintin, J., D. Buisson, S. Thoret, T. Cresteil, and G. Lewin. 2009. Semisynthesis and antiprolifer¬ative evaluation of a series of 3′- aminoflavones. Bioorg. Med. Chem. Lett. 19: 3502-3506.
132. Ramos, S. 2008. Cancer chemoprevention and chemotherapy: Dietary polyphenols and signal¬ling pathways. Mol. Nutr. Food Res. 52: 507-526.
133. Renaud, S. and M. de Lorgeril. 1992. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339: 1523-1526.
134. Riveiro, M. E., N. De Kimpe, A. Moglioni, R. Vazquez, F. Monczor, C. Shayo, and C. Davio. 2010. Coumarins: Old compounds with novel promising therapeutic perspectives. Curr. Med. Chem. 17: 1325-1338.
135. Saiko, M., Z. Pemberger, I. Horvath, I. Savinc, M. Grusch, N. Handler, T. Erker, W. Jaeger, M. Fritzer-Szekeres, and T. Szekeres. 2008. Novel resveratrol analogs induce apoptosis and cause cell cycle arrest in HT29 human colon cancer cells: Inhibition of ribonucleo¬tide reductase activity. Oncol. Rep. 19: 1621-1626.
136. Sánchez-del-Campo, L., F. Otón, A. Tárraga, J. Cabezas-Herrera, S. Chazarra, and J. Neptuno Rodríguez-López. 2008. Synthesis and biological activity of a 3,4,5-trimethoxybenzoyl ester analogue of epicatechin-3-gallate. J. Med. Chem. 51: 2018-2026.
137. Sánchez-del-Campo, L., A. Tarraga, M. F. Montenegro, J. Cabezas-Herrera, and J. N. Rodriguez-Lopez. 2009. Melanoma activation of 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin to a potent irreversible inhibitor of dihydrofolate reductase. Mol. Pharm. 6: 883-894.
138. Schneider, Y., P. Chabert, J. Stutzmann, D. Coelho, A. Fougerousse, F. Gosse, J.-F. Launay, R. Brouillard, and F. Raul. 2003. Resveratrol analog (Z)-3,5,4′-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization. Int. J. Cancer 107: 189-196.
139. Signorelli, P. and R. Ghidoni. 2005. Resveratrol as an anticancer nutrient: Molecular basis, open questions and promises. J. Nutr. Biochem. 16: 449-466.
140. Simoni, D., F. P. Invidiata, M. Eleopra, P. Marchetti, R. Rondanin, R. Baruchello, G. Grisolia et al. 2009. Design, synthesis and biological evaluation of novel stilbene-based antitu¬mor agents. Bioorg. Med. Chem. 17: 512-522.
141. Simoni, D., M. Rizzi, R. Rondanin, R. Baruchello, P. Marchetti, F. P. Invidiata, M. Labbozzetta et al. 2008. Antitumor effects of curcumin and structurally β-diketone modified analogs on multidrug resistant cancer cells. Bioorg. Med. Chem. Lett. 18: 845-849.
142. Simoni, D., M. Roberti, F. P. Invidiata, E. Aiello, S. Aiello, P. Marchetti, R. Baruchello et al. 2006. Stilbene-based anticancer agents: Resveratrol analogues active toward HL60 leuke¬mic cells with a non-specific phase mechanism. Bioorg. Med. Chem. Lett. 16: 3245-3248.
143. Singh, R. and H. Kaur. 2009. Advances in synthetic approaches for the preparation of combre¬tastatin-based anti-cancer agents. Synthesis 15: 2471-2491.
144. Souza da Silva, S. A., A. L. Souto, M. de Fatima Agra et al. 2004. A new arylnaphthalene type lignan from Cordia rufescens A. DC (Boraginaceas). Arkivok 6: 54-58.
145. Spatafora, C., G. Basini, L. Baioni, F. Grasselli, A. Sofia, and C. Tringali. 2009. Antiangiogenic resveratrol analogues by mild m-CPBA aromatic hydroxylation of 3,5-dimethoxystil¬benes. Nat. Prod. Comm. 4: 239-246.
146. Spatafora, C. and C. Tringali. 2007. Phenolic oxidative coupling in the biomimetic synthesis of heterocyclic lignans, neolignans and related compounds. In Targets in Heterocyclic Systems. Chemistry and Properties, Vol. 11, eds. O. A. Attanasi and D. Spinelli, pp. 284-312. Roma, Italy: Società Chimica Italiana.
147. Sporn, M. B., N. M. Dunlop, D. L. Newton, and J. M. Smith. 1976. Prevention of chemical car¬cinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc. 35: 1332-1338.
148. Srinivas, K. V., R. Y. Koteswara, I. Mahender, B. Das, K. V. S. Rama Krishna, K. Hara Kishore, and U. S. N. Murty. 2003. Flavonoids from Caesalpinia pulcherrima. Phytochemistry 63: 789-793.
149. Steward, W. P. and A. J. Gescher. 2008. Curcumin in cancer management: Recent results of analogue design and clinical studies and desirable future research. Mol. Nutr. Food Res. 52: 1005-1009.
150. Sun, A., Y. J. Lu, H. Hu, M. Shoji, D. C. Liotta, and J. P. Snyder. 2009. Curcumin analog cytotoxicity against breast cancer cells: Exploitation of a redox-dependent mechanism. Bioorg. Med. Chem. Lett. 19: 6627-6631.
151. Surh, Y. 1999. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat. Res. 428: 305-327.
152. Surh, Y. J. 2003. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 3: 768-780.
153. Takaoka, M. J. 1940. Of the phenolic substances of white hellebore (Veratrum grandiflorum Loes. fil.). J. Fac. Agric. Hokkaido 3: 1-16.
154. Thomasset, S. C., D. P. Berry, G. Garcea, T. Marczylo, W. P. Steward, and A. J. Gescher. 2006. Dietary polyphenolic phytochemicals-Promising cancer chemopreventive agents in humans? A review of their clinical properties. Int. J. Cancer 120: 451-458.
155. Tozer, G. M., C. Kanthou, and B. C. Baguley. 2005. Disrupting tumor blood vessels. Nat. Rev. Cancer 5: 423-435.
156. Tron, G. C., T. Pirali, G. Sorba, F. Pagliai, S. Busacca, and A. A. Genazzani. 2006. Medicinal chem¬istry of combretastatin A4: Present and future directions. J. Med. Chem. 49: 3033-3044.
157. Vogel, S., S. Ohmayer, G. Brunner, and J. Heilmann. 2008. Natural and non-natural prenylated chalcones: Synthesis, cytotoxicity and anti-oxidative activity. Bioorg. Med. Chem. 16: 4286-4293.
158. Walle, T. 2007. Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass? Semin. Cancer Biol. 17: 354-362.
159. Weber, W. M., L. A. Hunsaker, C. N. B.-M. Roybal, V. Ekaterina, S. F. Abcouwer, R. E. Royer, L. M. Deck, and D. L. Vander Jagt. 2006. Activation of NF kappa B is inhibited by cur¬cumin and related enones. Bioorg. Med. Chem. 14: 2450-2461.
160. Weng, C. J., Y. T. Yang, C. T. Ho, and G. C. Yen. 2009. Mechanisms of apoptotic effects induced by resveratrol, dibenzoylmethane, and their analogues on human lung carci¬noma cells. J. Agric. Food. Chem. 57: 5235-5243.
161. William, N. W. Jr., J. V. Heymach, E. S. Kim, and S. M. Lippman. 2009. Molecular targets for cancer chemoprevention. Nat. Rev. Drug Discov. 8: 213-223.
162. Xia, C., L. H. Li, L. Feng, and W. -X. Hu. 2008. Synthesis of trans-caffeate analogues and their bioactivities against HIV-1 integrase and cancer cell lines. Bioorg. Med. Chem. Lett. 18: 6553-6557.
163. Yamakoshi, H., H. Ohori, C. Kudo et al. 2010. Structure-activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof. Bioorg. Med. Chem. 18: 1083-1092.
164. Yang, C. S., S. Kim, G. Y. Yang, M.-J. Lee, J. Liao, J. Y. Chung, and C.-T. Ho. 1999. Inhibition of carcinogenesis by tea: Bioavailability of tea polyphenols and mechanisms of actions. Proc. Soc. Exp. Biol. Med. 220: 213-217.
165. Yerra, K. R., F. Shih-Hua, and T. Yew-Min. 2009. Synthesis and biological evaluation of 3′, 4′, 5′-trimethoxychalcone analogues as inhibitors of nitric oxide production and tumor cell proliferation. Bioorg. Med. Chem. 17: 7909-7914.
166. Yu, P.-F., H. Chen, J. Wang, C.-X. He, B. Cao, M. Li, N. Yang, Z.-Y. Lei, and M.-S. Cheng. 2008a. Design, synthesis and cytotoxicity of novel podophyllotoxin derivatives. Chem. Pharm. Bull. 56: 831-834.
167. Yu, Z., X. L. Qin, Y. Y. Gu, C. Di, Q. C. Cui, T. Jiang, S. B. Wan, and Q. P. Dou. 2008b. Prodrugs of fluoro-substituted benzoates of EGC as tumor cellular proteasome inhibi¬tors and apoptosis inducers. Int. J. Mol. Sci. 9: 951-961.
168. Zaveri, N. T. 2006. Green tea and its polyphenolic catechins: Medicinal uses in cancer and noncancer applications. Life Sci. 78: 2073-2080.